Activin A more prominently regulates muscle mass in primates than does GDF8
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Growth and differentiation factor 8 (GDF8) is a TGF-β superfamily member, and negative regulator of skeletal muscle mass. GDF8 inhibition results in prominent muscle growth in mice, but less impressive hypertrophy in primates, including man. Broad TGF-β inhibition suggests another family member negatively regulates muscle mass, and its blockade enhances muscle growth seen with GDF8-specific inhibition. Here we show that activin A is the long-sought second negative muscle regulator. Activin A specific inhibition, on top of GDF8 inhibition, leads to pronounced muscle hypertrophy and force production in mice and monkeys. Inhibition of these two ligands mimics the hypertrophy seen with broad TGF-β blockers, while avoiding the adverse effects due to inhibition of multiple family members. Altogether, we identify activin A as a second negative regulator of muscle mass, and suggest that inhibition of both ligands provides a preferred therapeutic approach, which maximizes the benefit:risk ratio for muscle diseases in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have previously demonstrated that growth differentiation factor-8 (GDF8; also known as myostatin) and activin A (ActA) are the two major ligands mediating the muscle-minimization actions of ActRIIA/B receptors22,26–30.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“combining these blocking antibodies results in much greater increases in muscle than either of the antibodies individually, with dual blockade matching the muscle growth induced by broader ActRIIA/B pathway blockade in both mice and non-human primates (NHPs)28,31”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“The function of MSTN in muscle is at least partially redundant with that of another TGF-β family member, activin A (13–16).”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [16]
In the citing paper
“However, this effect on glucose tolerance was not observed in mice treated with antibodies specific to two ActRII ligands, GDF-8 and activin A, suggesting the potential involvement of additional ActRII ligands in the regulation of glucose homeostasis [36].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [36]
In the citing paper
“Notably, administration of a soluble ActRIIB fragment impaired glucose tolerance in lean mice, which was correlated with increased spleen and pancreas weights [36].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., Miller, C., Regalado, S. G., Loffredo, F. S., Pancoast, J. R., et al. (2014) · Science · doi:10.1126/science.1251152 · Cited by 824
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
David, L., Mallet, C., Mazerbourg, S., Feige, J.-J., & Bailly, S. (2007) · Blood · doi:10.1182/blood-2006-07-034124 · Cited by 708
Research works printed but not linked: 1
- Schwarzkopf, M., Coletti, D., Marazzi, G. & Sassoon, D. Chronic p53 leads to skeletal muscle atrophy and muscle stem cell perturbation. Basic Appl. Myol. 18, 131–138 (2008).
Cited by
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 258
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
Yung, L.-M., Yang, P., Joshi, S., Augur, Z. M., Kim, S. S. J., Bocobo, G. A., Dinter, T., Troncone, L., Chen, P.-S., McNeil, M. E., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5660 · Cited by 248
“GDF8 is highly homologous to GDF11 (~90%) (33) and overlaps in function with GDF11 and activin A in regulating muscle mass and myocyte hypertrophy based on genetic loss-of-function and pharmacologic experiments (34, 35).”
BackgroundActivin A in Mammalian Physiology
Bloise, E., Ciarmela, P., Dela Cruz, C., Luisi, S., Petraglia, F., & Reis, F. M. (2019) · Physiological Reviews · doi:10.1152/physrev.00002.2018 · Cited by 199
“Activin A regulates muscle contractile properties (468), muscle force production (219), and muscle mitochondrial oxidative phosphorylation (357).”
BackgroundMolecular Mechanisms of Skeletal Muscle Hypertrophy
Schiaffino, S., Reggiani, C., Akimoto, T., & Blaauw, B. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200568 · Cited by 157
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease
Wang, X. H., Mitch, W. E., & Price, S. R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00498-0 · Cited by 170
The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals
Aiello, D., Patel, K., & Lasagna, E. (2018) · Animal Genetics · doi:10.1111/age.12696 · Cited by 162
Mitochondria as a Target for Mitigating Sarcopenia
Coen, P. M., Musci, R. V., Hinkley, J. M., & Miller, B. F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01883 · Cited by 154
“It was recently demonstrated that inhibition of activin A in primates enhanced muscle growth (Latres et al., 2017).”
BackgroundOsteogenesis Imperfecta: New Perspectives From Clinical and Translational Research
Tauer, J. T., Robinson, M., & Rauch, F. (2019) · JBMR Plus · doi:10.1002/jbm4.10174 · Cited by 158
“Myostatin and activin A are two members of the TGFb family that inhibit muscle growth by signaling through the activin receptor 2B.((123)) A soluble activin receptor 2B that inhibits both myostatin and activin A led to a marked increase in muscle and bone mass in oim mice.”
BackgroundTargeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S.-J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 143
“Studies in mice have shown that targeting MSTN alone is sufficient to induce muscle growth but that targeting MSTN along with other TGF-β family members, most notably activin A, can have a much greater effect (24, 26, 33, 40, 41), and this seems to have been borne out in the clinical trials as well.”
BackgroundInfluentialMariot, V., Joubert, R., Hourdé, C., Féasson, L., Hanna, M., Muntoni, F., Maisonobe, T., Servais, L., Bogni, C., Le Panse, R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01486-4 · Cited by 136
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
“Recent work examining the relative contribution of various ligands, activin A, activin B, beyond myostatin, unveiled a strong synergistic response upon blockade of both activin and myostatin (18, 19), with some cross-species difference between mice and primates (18).”
BackgroundMethodMyostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135
Seo, M.-W., Jung, S.-W., Kim, S.-W., Lee, J.-M., Jung, H. C., & Song, J.-K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136762 · Cited by 130
“GDF-8, GDF-15, and activin A are potent negative regulators of muscle homeostasis in humans [14].”
BackgroundNunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126
“Notably, administration of a soluble ActRIIB fragment impaired glucose tolerance in lean mice, which was correlated with increased spleen and pancreas weights [36].”
BackgroundTargeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014716117 · Cited by 115
“The function of MSTN in muscle is at least partially redundant with that of another TGF-β family member, activin A (13 – 16).”
The clinical impact and biological mechanisms of skeletal muscle aging
Aversa, Z., Zhang, X., Fielding, R. A., Lanza, I., & LeBrasseur, N. K. (2019) · Bone · doi:10.1016/j.bone.2019.05.021 · Cited by 101
Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation
Haberecht-Müller, S., Krüger, E., & Fielitz, J. (2021) · Biomolecules · doi:10.3390/biom11091327 · Cited by 108
Ubiquitin Ligases at the Heart of Skeletal Muscle Atrophy Control
Peris-Moreno, D., Cussonneau, L., Combaret, L., Polge, C., & Taillandier, D. (2021) · Molecules · doi:10.3390/molecules26020407 · Cited by 95
“Similarly, Activin A ligand negatively regulates muscle mass by binding to the same receptor than myostatin and by activating the same intracellular pathway [70–72].”
Current pharmacotherapies for sarcopenia
Hardee, J. P., & Lynch, G. S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1622093 · Cited by 84
“have previously found that combined activin A and myostatin inhibition enhanced muscle growth and force production in mice and monkeys [42].”
BackgroundSupraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15
Jones, J. E., Cadena, S. M., Gong, C., Wang, X., Chen, Z., Wang, S. X., Vickers, C., Chen, H., Lach-Trifilieff, E., Hadcock, J. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.044 · Cited by 85
Abati, E., Manini, A., Comi, G. P., & Corti, S. P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04408-w · Cited by 89
“Among those, activin A is a key ligand that works with myostatin to restrict muscle growth [49, 52].”
BackgroundMethodMyostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Fielding, R. A., Atkinson, E. J., Aversa, Z., White, T. A., Heeren, A. A., Achenbach, S. J., Mielke, M. M., Cummings, S. R., Pahor, M., Leeuwenburgh, C., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00685-2 · Cited by 75
“Antibody-based inhibition of circulating activin A results in significant increases in muscle growth and force in mice and lean mass in cynomolgus monkeys [34].”
BackgroundNachit, M., & Leclercq, I. A. (2019) · Clinical Science · doi:10.1042/cs20180421 · Cited by 73
Han, X., Møller, L. L. V., De Groote, E., Bojsen‐Møller, K. N., Davey, J., Henríquez‐Olguin, C., Li, Z., Knudsen, J. R., Jensen, T. E., Madsbad, S., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12474 · Cited by 75
“A major regulator of muscle mass is the transforming growth factor β (TGF-β) superfamily, including activin A and myostatin, among which activin A is most relevant to humans.(9) Activin A”
BackgroundSolagna, F., Tezze, C., Lindenmeyer, M. T., Lu, S. Y., Wu, G., Liu, S., Zhao, Y., Mitchell, R., Meyer, C., Omairi, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135821 · Cited by 68
“Importantly, transcriptional profiles of myofibroblasts during renal fibrosis show, among the most upregulated genes, Inhba (57), which encodes the secreted protein activin A that acts both as a growth and differentiation factor (58, 59) and is a potent inhibitor of muscle growth (35, 60).”
BackgroundLocally acting ACE‐083 increases muscle volume in healthy volunteers
Glasser, C. E., Gartner, M. R., Wilson, D., Miller, B., Sherman, M. L., & Attie, K. M. (2018) · Muscle & Nerve · doi:10.1002/mus.26113 · Cited by 63
Peradze, N., Farr, O. M., Perakakis, N., Lázaro, I., Sala-Vila, A., & Mantzoros, C. S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0945-7 · Cited by 61
Principles of the activin receptor signaling pathway and its inhibition
Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 62
Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes
Verma, A. K., Suragani, R. N. V. S., Aluri, S., Shah, N. N., Bhagat, T. D., Alexander, M. J., Komrokji, R. S., & Kumar, R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133678 · Cited by 64
Analytical Approaches in Human Sports Drug Testing: Recent Advances, Challenges, and Solutions
Thevis, M., Walpurgis, K., & Thomas, A. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04639 · Cited by 60
Lee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59
“In previous studies, we showed that the function of MSTN in limiting muscle growth is redundant with that of at least one other TGF-β family member (13, 14), and several studies have implicated activin A as at least one of the key cooperating ligands (15, 16).”
Pearsall, R. S., Davies, M. V., Cannell, M., Li, J., Widrick, J. J., Mulivor, A. W., Wallner, S., Troy, M., Spaits, M. S., Liharska, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47818-w · Cited by 64
Iskenderian, A., Liu, N., Deng, Q., Huang, Y. L., Shen, C., Palmieri, K. J., Crooker, R., Lundberg, D. M., Kastrapeli, N., Pescatore, B., et al. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0180-z · Cited by 59
The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis
Egerman, M. A., & Glass, D. J. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1610722 · Cited by 57
“In adult primates, ActivinA has recently been shown to have a more significant impact on muscle than myostatin (Latres et al. 2017), further demonstrating that the three ligands that signal through the common ActRII receptors have similar effects, and can substitute for each other (Latres et al.…”
BackgroundMastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59485-9 · Cited by 53
“…GDF8 and ActA are the two major ligands which mediate the muscle minimization actions of the ActRIIA/B receptors in non-obese mice and NHPs 22,28,30 , and we have further shown that dual blockade of GDF8 and ActA led to much larger increases in muscle mass than blocking either ligand…”
InfluentialSelf-citationJang, J., Park, S., Kim, Y., Jung, J., Lee, J., Chang, Y., Lee, S. P., Park, B., Wolfe, R. R., Choi, C. S., et al. (2021) · Nutrients · doi:10.3390/nu13051508 · Cited by 57
Muscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis
Ongaro, L., Zhou, X., Wáng, Y., Schultz, H., Zhou, Z., Buddle, E. R. S., Brûlé, E., Lin, Y., Schang, G., Hagg, A., et al. (2025) · Science · doi:10.1126/science.adi4736 · Cited by 53
Development of Pharmacotherapies for the Treatment of Sarcopenia
Rooks, D., & Roubenoff, R. (2019) · The Journal of Frailty & Aging · doi:10.14283/jfa.2019.11 · Cited by 46
“Activin A, another ligand that signals through the ActRII, has recently been proposed to have a greater effect on regulating muscle mass in primates than myostatin (113).”
Signaling pathways affected by mutations causing osteogenesis imperfecta
Etich, J., Rehberg, M., Eckes, B., Sengle, G., Semler, O., & Zaucke, F. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109789 · Cited by 53
Vanhoutte, F. P., Liang, S., Ruddy, M. K., Zhao, A., Drewery, T., Wang, Y., DelGizzi, R., Forleo‐Neto, E., Rajadhyaksha, M., Herman, G. A., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1638 · Cited by 49
Sarcopenia in the era of precision health: Toward personalized interventions for healthy longevity
Chen, L. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001164 · Cited by 51
“77”
The elusive promise of myostatin inhibition for muscular dystrophy
Wagner, K. R. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000853 · Cited by 51
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Zheng, Y., Feng, J., Yu, Y., Ling, M., & Wang, X. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01493-2 · Cited by 50
“These data provide a supportive basis for considering the combined inhibition of MSTN and activin A antibodies as a potential treatment approach for individuals suffering from muscle atrophy associated with muscle-wasting disorders (Latres et al. 2017).”
Hoogaars, W. M. H., & Jaspers, R. T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_8 · Cited by 45
Cardiac ageing: from hallmarks to therapeutic opportunities
Hastings, M. H., Zhou, Q., Wu, C., Shabani, P., Huang, S., Yu, X., Singh, A. P., Guseh, J. S., Li, H., Lerchenmüller, C., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae124 · Cited by 52
Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA
Schumann, C., Nguyen, D. X., Norgard, M., Bortnyak, Y., Korzun, T., Chan, S., Lorenz, A. S., Moses, A. S., Albarqi, H. A., Wong, L., et al. (2018) · Theranostics · doi:10.7150/thno.27847 · Cited by 42
“concluded that two TGF-β superfamily proteins, myostatin and activin A, are key negative regulators of muscle growth in primates and mice, and activin A plays a more significant role than myostatin in regulating muscle mass in primates [16].”
BackgroundCancer-Associated Cachexia: A Systemic Consequence of Cancer Progression
Biswas, A., & Acharyya, S. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033642 · Cited by 47
“In primates, however, simultaneous inhibition of activin A and myostatin was required to induce robust hypertrophic effects with enhanced force production (Latres et al. 2017).”
BackgroundNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Activin A does not drive post-traumatic heterotopic ossification
Hwang, C. D., Pagani, C. A., Das, N., Marini, S., Huber, A. K., Xie, L., Jimenez, J., Brydges, S. D., Lim, W. K., Nannuru, K. C., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115473 · Cited by 39
Self-citationFielding, R. A., Atkinson, E. J., Aversa, Z., White, T. A., Heeren, A. A., Mielke, M. M., Cummings, S. R., Pahor, M., Leeuwenburgh, C., & LeBrasseur, N. K. (2024) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glad257 · Cited by 38
Circulating Follistatin and Activin A and Their Regulation by Insulin in Obesity and Type 2 Diabetes
Sylow, L., Vind, B. F., Kruse, R., Møller, P. M., Wojtaszewski, J. F. P., Richter, E. A., & Højlund, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa090 · Cited by 36
Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?
Rybtsova, N., Berezina, T. N., Kagansky, A., & Александрович, Р. С. (2020) · Biomedicines · doi:10.3390/biomedicines8120615 · Cited by 36
Osteogenesis Imperfecta: Muscle–Bone Interactions when Bi-directionally Compromised
Phillips, C. L., & Jeong, Y. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0456-6 · Cited by 33
Deciphering Myostatin’s Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases
Omosule, C. L., & Phillips, C. L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.662908 · Cited by 34
“Other natural inhibitors of myostatin include follistatin, follistatin-like 3 (FSTL-3), and GDF-associated serum protein 1 and 2 (GASP-1 and -2; Figure 1A; Laurent et al., 2016).”
BackgroundSystemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury
Magga, J. M., Vainio, L., Kilpiö, T., Hulmi, J. J., Taponen, S., Lin, R., Ramste, M. O., Szabó, Z., Gao, E., Rahtu‐Korpela, L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.013 · Cited by 33
“In addition to BMPs,(28,29) myostatin and activin A are potent regulators of muscle growth.(30) Myostatin is predominantly expressed in the skeletal muscle but also to lower extent in the heart.”
BackgroundLiver fibrosis-induced muscle atrophy is mediated by elevated levels of circulating TNFα
Kurosawa, T., Goto, M., Kaji, N., Aikiyo, S., Mihara, T., Ikemoto‐Uezumi, M., Toyoda, M., Kanazawa, N., Nakazawa, T., Hori, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03353-5 · Cited by 31
Mediators and clinical treatment for cancer cachexia: a systematic review
Cao, Z., Scott, A. M., Hoogenraad, N. J., & Osellame, L. D. (2021) · JCSM Rapid Communications · doi:10.1002/rco2.30 · Cited by 34
The Functional Role of Long Non-Coding RNA in Myogenesis and Skeletal Muscle Atrophy
Hitachi, K., Honda, M., & Tsuchida, K. (2022) · Cells · doi:10.3390/cells11152291 · Cited by 44
“Activin appears to be more potent than myostatin in inducing muscle atrophy in primates [31].”
BackgroundLi, J., Fredericks, M., Cannell, M., Wang, K., Sako, D., Maguire, M. C., Grenha, R., Liharska, K., Krishnan, L., Bloom, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138634 · Cited by 31
“Based mainly on studies in WT mice, others have proposed that concurrent inhibition of activin A and GDF8 with cognate antibodies increases muscle mass and force generation just as effectively as multiligand inhibition with ActRIIB-Fc (19).”
BackgroundResultMuntoni, F., Byrne, B. J., McMillan, H. J., Ryan, M. M., Wong, B. L. Y., Dukart, J., Bansal, A., Cosson, V. F., Dreghici, R. D., Guridi, M., et al. (2024) · Neurology and Therapy · doi:10.1007/s40120-023-00570-w · Cited by 31
“Disruption of the myostatin pathway in these mice improved dystrophic pathology [32, 53, 64, 65]; however, in the literature, circulating levels of myostatin have been reported to be 4-to 18-fold lower in monkeys, rats, and humans than in mice [66].”
BackgroundCho, K., Choi, D., Kim, Y., Kim, J.-W., Ryu, K., & Woo, S. (2021) · Cells · doi:10.3390/cells10082169 · Cited by 31
“Activin A is a member of the transforming growth factor beta (TGF-β) family and a well-known negative regulator of skeletal muscle mass [8].”
BackgroundCussonneau, L., Boyer, C., Brun, C., Deval, C., Loizon, E., Meugnier, E., Guéret, É., Dubois, E., Taillandier, D., Polge, C., et al. (2021) · Cells · doi:10.3390/cells10081873 · Cited by 29
“In-deed, the gene disruption of two of its ligands Myostatin ( MSTN ) or Activin A ( INHBA ), and the inhibition of their shared receptor ActRIIB ( ACVR2B ) promote a profound muscle hypertrophy phenotype in various conditions and species [78–81].”
Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle
Castonguay, R., Lachey, J. L., Wallner, S., Strand, J., Liharska, K., Watanabe, A. E., Cannell, M., Davies, M. V., Sako, D., Troy, M., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252304 · Cited by 30
“, 2017) and may be of particular importance in primates (Latres et al., 2017).”
BackgroundInfluentialTauer, J. T., & Rauch, F. (2019) · Bone · doi:10.1016/j.bone.2019.115036 · Cited by 29
Hillege, M. M., Shi, A., Galli, R., Wu, G., Bertolino, P., Hoogaars, W. M. H., & Jaspers, R. T. (2022) · eLife · doi:10.7554/elife.77610 · Cited by 29
Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification
Felix-Ilemhenbhio, F., Pickering, G. A. E., Kiss‐Toth, E., & Wilkinson, J. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136983 · Cited by 28
INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling
Li, F., Gu, L., Tong, Y.-L., Chen, R.-Q., Chen, S., Yu, X., Liu, N., Lu, J.-L., Si, Y., Sun, J., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01381-x · Cited by 27
“Garetosmab shares similar binding af fi nity to activin A among human, mouse and monkey as activin A is conserved across these species [41].”
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy
Servais, L., Lair, L. L., Connolly, A. M., Byrne, B. J., Chen, K. S., Coric, V., Qureshi, I., Durham, S., Campbell, D. J., Maclaine, G. D. H., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910273 · Cited by 30
“…tissue and reduces the capacity for wasting in muscular tissue, which could result from activin A signaling if myostatin alone were inhibited [52]. potentially minimizes o ff -target e ff ects resulting from activin type II receptor blockage in nonmuscular tissue and reduces the capacity for…”
Bai, W., Zhang, Y., Ma, J., Du, M., Xu, H., Wang, J., Zhang, L., Li, W., Hou, Y., Liu, X., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04680-w · Cited by 27
“An increase in fast glycolytic muscle fiber numbers leads to muscle fiber thickening, muscle hypertrophy, and greater muscle mass [34, 35], but results in whiter meat color and the decline of meat pH value after slaughter [36].”
BackgroundSignaling networks governing skeletal muscle growth, atrophy, and cachexia
Joshi, A. S., da Silva, M. T., Kumar, S., & Kumar, A. (2025) · Skeletal Muscle · doi:10.1186/s13395-025-00397-z · Cited by 27
“Indeed, Activin A is another key negative regulator of skeletal muscle growth confirmed by the findings that antibody-mediated inhibition of GDF8 and Activin A leads to a synergistic improvement in muscle mass in mice and monkeys [111].”
Hanada, K., Fukasawa, K., Hinata, H., Imai, S., Takayama, K., Hirai, H., Ohfusa, R., Hayashi, Y., & Itoh, F. (2022) · Cancer Science · doi:10.1111/cas.15491 · Cited by 27
Korzun, T., Moses, A. S., Kim, J., Patel, S., Schumann, C., Levasseur, P. R., Diba, P., Olson, B. G., Rebola, K. G. D. O., Norgard, M. A., et al. (2022) · Small · doi:10.1002/smll.202204436 · Cited by 28
Lodberg, A., van der Eerden, B. C. J., Boers-Sijmons, B., Thomsen, J. S., Brüel, A., van Leeuwen, J. P. T. M., & Eijken, M. (2019) · The FASEB Journal · doi:10.1096/fj.201801969rr · Cited by 25
The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer
Seachrist, D. D., & Keri, R. A. (2019) · Endocrinology · doi:10.1210/en.2019-00015 · Cited by 26
Gonzalez Trotter, D., Donahue, S., Wynne, C., Ali, S., Parasoglou, P., Boyapati, A., Mohammadi, K., Musser, B. J., Meier, P., Mastaitis, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59380-3 · Cited by 23
“…A (ActA) might be the key second negative regulator acting viaActRIIA/B, based onstudies inmouseand non-human primates showing that joint blockade of GDF8 and ActA with monoclonal antibodies led to synergistic increases in muscle mass, similar to that seen with broader ActRIIA/B blockade 14 .”
InfluentialSelf-citationActivin A Causes Muscle Atrophy through MEF2C-Dependent Impaired Myogenesis
Loumaye, A., Lause, P., Zhong, X., Zimmers, T. A., Bindels, L. B., & Thissen, J. (2022) · Cells · doi:10.3390/cells11071119 · Cited by 25
Activation of β-catenin in mesenchymal progenitors leads to muscle mass loss
Kajabadi, N., Low, M., Jacques, E., Lad, H., Tung, L. W., Babaeijandaghi, F., Gamu, D., Zelada, D., Wong, C. K., Chang, C.-K., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.02.009 · Cited by 23
Omosule, C. L., Gremminger, V. L., AGUILLARD, A., Jeong, Y., Harrelson, E. N., Miloscio, L., Mastaitis, J. W., Rafique, A., Kleiner, S., Pfeiffer, F. M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4223 · Cited by 21
“Myostatin is a TGF-β superfamily member and known regulator of muscle mass in humans,((23)) other primates,((25)) cattle,((26)) and rodents.”
BackgroundMethodSelf-citationKumari, R., Irudayam, M. J., Abdallah, Q. A., Jones, T. L., Mims, T. S., Puchowicz, M. A., Pierre, J. F., & Brown, C. W. (2021) · The FASEB Journal · doi:10.1096/fj.202101244r · Cited by 22
Targeting Soluble TGF-β Factors
Becher, C., Wits, M., de Man, F. S., Sánchez‐Duffhues, G., & Goumans, M. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.04.005 · Cited by 23
Overexpression of CD36 in mammary fibroblasts suppresses colony growth in breast cancer cell lines
Cheng, Q., Jabbari, K., Winkelmaier, G., Andersen, C., Yaswen, P., Khoshdeli, M., & Parvin, B. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.061 · Cited by 21
“However, because activin A also regulates muscle mass[30] and modulates the function of immune cells [31], its clinical utility requires additional investigation.”
BackgroundOzawa, T., Morikawa, M., Morishita, Y., Ogikubo, K., Itoh, F., Koinuma, D., Nygren, P., & Miyazono, K. (2021) · iScience · doi:10.1016/j.isci.2021.102488 · Cited by 20
Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies
Baik, A. D., Calafati, P., Zhang, X., Aaron, N. A., Mehra, A., Møller-Tank, S., Miloscio, L., Praggastis, M., Giovannone, N., Pan, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.020 · Cited by 21
“To determine whether AAV a-hCD631 scFv:GAA treatment affected TA muscle function, ex vivo force was measured 6 months after dosing as previously described.(47) Briefly, TA muscles were removed from anesthetized Pompe untreated, AAV a-hCD631 scFv:GAA, and GAA wild-type mice.”
MethodSelf-citationLiu, Y., Lehar, A., Rydzik, R., Chandok, H., Lee, Y., Youngstrom, D. W., George, J., Matzuk, M. M., Germain‐Lee, E. L., & Lee, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111401118 · Cited by 21
Walpurgis, K., Thomas, A., & Thevis, M. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2729 · Cited by 20
“Skeletal muscle mass and function are negatively regulated by cytokines of the transforming growth factor beta (TGF-β) superfamily such as myostatin (growth differentiation factor-8, GDF-8) and activin A.(1,2) Especially the regulative role of myostatin has been extensively studied in the past and the knockout of the…”
BackgroundOmosule, C. L., Joseph, D., Weiler, B., Gremminger, V. L., Silvey, S., Jeong, Y., Rafique, A., Krueger, P., Kleiner, S., & Phillips, C. L. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4529 · Cited by 19
“In SCID mice, 3 week inhibition of activin A and myostatin using monoclonal antibodies improved muscle force production.((28)) Further, after only 3 days of sActRIIB-mFc treatment, orchidectomized C57BL6 exhibited increases in muscle force production, as did 18-month-old mice following 30 days of sActRIIB-mFc treatmen…”
BackgroundMethodResultInfluentialSelf-citationInactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension
Ryanto, G. R. T., Musthafa, A., Hara, T., & Emoto, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043332 · Cited by 19
“The presence of activin A is also known to negatively regulate muscle mass, which is of major relevance in muscle dystrophy [77].”
Prostate tumor–derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia
Pan, C., Jaiswal, N., Zulia, Y., Singh, S. T., Sha, K., Mohler, J. L., Eng, K. H., Chakkalakal, J. V., Krolewski, J. J., & Nastiuk, K. L. (2020) · JCI Insight · doi:10.1172/jci.insight.127018 · Cited by 17
“weekly for 10 weeks) shown to neutralize GDF11 activity (40, 44, 46).”
BackgroundHow Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva
Srinivasan, D., Arostegui, M., Goebel, E. J., Hart, K. N., Aykul, S., Lees‐Shepard, J. B., Idone, V. J., Hatsell, S. J., & Economides, A. N. (2024) · Biomolecules · doi:10.3390/biom14010101 · Cited by 17
“This set of clues led us to test whether Activin A can induce HO or, conversely, whether the inhibition of Activin A, using the monoclonal antibody REGN2477 [44], could inhibit HO in FOP mice.”
MethodGrunow, J. J., Reiher, K., Carbon, N. M., Engelhardt, L. J., Mai, K., Koch, S., Schefold, J. C., Z'Graggen, W. J., Schaller, S. J., Fielitz, J., et al. (2022) · Critical Care · doi:10.1186/s13054-022-04101-1 · Cited by 16
MacDonnell, S. M., Megna, J. S., Ruan, Q., Zhu, O., Halász, G., Jasewicz, D., Powers, K. M., Hock, E., Molina‐Portela, M. D. P., Jin, X., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1038114 · Cited by 15
“Cells were exposed to 1 nM Activin A (R&D Systems) for 30 min in the presence or absence of anti–Activin A (10 nM REGN2477) or isotype control (10 nM REGN1945) monoclonal antibodies (Regeneron Pharmaceuticals, Tarrytown, NY, USA) (19, 20).”
MethodOjima, C., Noguchi, Y., Miyamoto, T., Saito, Y., Orihashi, H., Yoshimatsu, Y., Watabe, T., Takayama, K., Hayashi, Y., & Itoh, F. (2020) · Cancer Science · doi:10.1111/cas.14520 · Cited by 16
Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions
Thomasius, F. E., Pesta, D. H., & Rittweger, J. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15877 · Cited by 17
“138 Another drawback is that gains in muscle mass did not always translate into improved functional outcomes in human trials.”
TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass
Hagg, A., Kharoud, S., Goodchild, G., Goodman, C. A., Chen, J. L., Thomson, R. E., Qian, H., Gregorevic, P., Harrison, C. A., & Walton, K. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.560225 · Cited by 14
“To date, soluble activin type II receptors (sActRIIA, sActRIIB), ligand-targeting antibodies, and follistatin have proven the most efficacious therapeutic reagents in mice (Zhou et al., 2010; Winbanks et al., 2012; Latres et al., 2017), and humans (Attie et al., 2013; Campbell et al., 2017).”
BackgroundStructures of activin ligand traps using natural sets of type I and type II TGFβ receptors
Goebel, E. J., Kattamuri, C., Gipson, G. R., Krishnan, L., Chavez, M., Czepnik, M., Maguire, M. C., Grenha, R., Håkansson, M., Logan, D. T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103590 · Cited by 15
“This is in part due to functional redundancy with several activin ligands, highlighting the need for broader spectrum inhibitors (Chen et al., 2017; Latres et al., 2017).”
BackgroundTakayama, K., Hitachi, K., Okamoto, H., Saitoh, M., Odagiri, M., Ohfusa, R., Shimada, T., Taguchi, A., Taniguchi, A., Tsuchida, K., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00705 · Cited by 14
Self-citationWalpurgis, K., Weigand, T., Knoop, A., Thomas, A., Reichel, C., Dellanna, F., & Thevis, M. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2925 · Cited by 14
Therapeutic strategies to modulate gut microbial health: Approaches for sarcopenia management.
Das, S., Preethi, B., Kushwaha, S., & Shrivastava, R. (2024) · PubMed · doi:10.14670/hh-18-730 · Cited by 16
Metadata
- Authors
- Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., Willer, T., Bai, Y., Hae Kim, J., Rafique, A., Jaspers, S., Stitt, T., Murphy, A. J., Yancopoulos, G. D., & Gromada, J.
- Affiliations
- Regeneron (United States) (US)
- Corresponding author
- Gromada, Jesper
- ORCID
- Venue
- Nature Communications
- Published
- 2017-04-28
- Volume
- 8
- Issue
- 1
- Pages
- 15153-15153
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5414365
- OpenAlex
- W2609426395
- Semantic Scholar
- 2e417ec4d417ebe167247c3466c130be75b2cef3
- Cited by
- 185
- References
- 65
- Citations by year
- 2026: 22 · 2025: 12 · 2024: 22 · 2023: 19 · 2022: 17 · 2021: 29 · 2020: 31 · 2019: 20 · 2018: 11 · 2017: 2
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
- Keywords
- activin A, myostatin, skeletal muscle mass, muscle hypertrophy, TGF-beta superfamily, muscle growth, muscle force production, primates
- MeSH terms
- Animals, Antibodies, Monoclonal, Dexamethasone, Humans, Hypertrophy, Isometric Contraction, Macaca fascicularis, Male, Mice, Inbred C57BL, Muscle Hypotonia, Body Mass Index, Mice, SCID, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Rats, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.